Treating autoimmune disease by targeting CD8+ T suppressor cells

Expert Opinion on Biological Therapy

Volumn 9, Issue 8, 2009, Pages 951-965

  Konya, Christine ^a   Goronzy, Jorg J ^a   Weyand, Cornelia M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune disease; T cells; T suppressor cells

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; GLATIRAMER; GLUCOCORTICOID; HISTONE H4; HISTONE PEPTIDE H4[71-94] PEPTIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN CONSENSUS PEPTIDE; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 16; METHOTREXATE; MONOCLONAL ANTIBODY CD3; STEROID; T LYMPHOCYTE RECEPTOR; TEPLIZUMAB; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; DENDRITIC CELL; ENTERITIS; HUMAN; HYPERGAMMAGLOBULINEMIA; IMMUNE RESPONSE; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE FUNCTION; MULTIPLE SCLEROSIS; NONHUMAN; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SUPPRESSOR CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE SUBPOPULATION;

ALLERGY AND IMMUNOLOGY; ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BIOLOGICAL THERAPY; CD8-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE SYSTEM; INFLAMMATORY BOWEL DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS;

EID: 67650699325     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903020759     Document Type: Review

References (68)

1. Nishizuka Y, Sakakura T. Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science 1969;166(906):753-755
2. Gershon RK, Cohen P, Hencin R, Liebhaber SA. Suppressor T cells. J Immunol 1972;108(3):586-590
3. Cantor H, Hugenberger J, McVay-Boudreau L, et al. Immunoregulatory circuits among T-cell sets. Identification of a subpopulation of T-helper cells that induces feedback inhibition. J Exp Med 1978;148(4):871-877 (Pubitemid 9034256)
4. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155(3):1151-1164
5. + regulatory T cells control Leishmania major persistence and immunity. Nature 2002;420(6915):502-507
6. + Ts cells, their potential mechanism of suppression, and their role in transplant rejection.
7. Kapp JA, Honjo K, Kapp LM, et al. TCR transgenic CD8+ T cells activated in the presence of TGFβ express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection. Int Immunol 2006;18(11):1549-1562 (Pubitemid 44605576)
8. Karlsson I, Malleret B, Brochard P, et al. FoxP3+ CD25+ CD8+ T-cell induction during primary simian immunodeficiency virus infection in cynomolgus macaques correlates with low CD4+ T-cell activation and high viral load. J Virol 2007;81(24):13444-13455 (Pubitemid 350247840)
9. Shao L, Jacobs AR, Johnson VV, Mayer L. Activation of CD8+ regulatory T cells by human placental trophoblasts. J Immunol 2005;174(12):7539-7547 (Pubitemid 40806257)
10. Sugita S, Futagami Y, Horie S, Mochizuki M. Transforming growth factor β-producing Foxp3+CD8+CD25+ T cells induced by iris pigment epithelial cells display regulatory phenotype and acquire regulatory functions. Exp Eye Res 2007;85(5):626-636 (Pubitemid 47633575)
11. + regulatory thymocytes. Blood 2003;102(12):4107- 4114
12. + regulatory T cells recognize activated T cells via conventional MHC class I-αβTCR interaction and become IL-10-producing active regulatory cells. Int Immunol 2008;20(7):937-947
13. Filaci G, Fravega M, Negrini S, et al. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+ CD28- T cells and inhibit both T-cell proliferation and CTL function. Hum Immunol 2004;65(2):142-156 (Pubitemid 38224140)
14. Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 1996;184(1):19-29 (Pubitemid 26247211)
15. + CD28- regulatory T cells. Hum Immunol 2008;69(11):745-750
16. + regulatory T cells by continuous antigen stimulation. Eur J Immunol 2008;38(3):640-646
17. + regulatory T cells. Mol Immunol 2008;45(10):2937-2950
18. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54(6):1763-1769 (Pubitemid 40770766)
19. + Ts cells.
20. Joosten SA, van Meijgaarden KE, Savage ND, et al. Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci USA 2007;104(19):8029-8034 (Pubitemid 47185870)
21. Uss E, Rowshani AT, Hooibrink B, et al. CD103 is a marker for alloantigen-induced regulatory CD8+ T cells. J Immunol 2006;177(5):2775-2783 (Pubitemid 44277792)
22. Uss E, Yong SL, Hooibrink B, et al. Rapamycin enhances the number of alloantigen-induced human CD103+ CD8+ regulatory T cells in vitro. Transplantation 2007;83(8):1098-1106 • This study shows that some of our current immunosuppressive medications might function by targeting CD8+ Ts cells. (Pubitemid 46659122)
23. Allez M, Brimnes J, Dotan I, Mayer L. Expansion of CD8+ T cells with regulatory function after interaction with intestinal epithelial cells. Gastroenterology 2002;123(5):1516-1526 (Pubitemid 35231652)
24. Yio XY, Mayer L. Characterization of a 180-kDa intestinal epithelial cell membrane glycoprotein, gp180. A candidate molecule mediating T cell-epithelial cell interactions. J Biol Chem 1997;272(19):12786-12792 (Pubitemid 27203379)
25. Jarvis LB, Matyszak MK, Duggleby RC, et al. Autoreactive human peripheral blood CD8+ T cells with a regulatory phenotype and function. Eur J Immunol 2005;35(10):2896-2908 (Pubitemid 41555085)
26. Gilliet M, Liu YJ. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 2002;195(6):695-704 (Pubitemid 34259715)
27. Wei S, Kryczek I, Zou L, et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res 2005;65(12):5020-5026 (Pubitemid 40827308)
28. + CD28- regulatory T cells. J Immunol 1998;161(10):5193-5202
29. Li J, Liu Z, Jiang S, et al. T suppressor lymphocytes inhibit NF-κB-mediated transcription of CD86 gene in APC. J Immunol 1999;163(12):6386-6392
30. Chang CC, Ciubotariu R, Manavalan JS, et al. Tolerization of dendritic cells by TS cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002;3(3):237-243 (Pubitemid 34218114)
31. + T suppressor cells and the ILT3 master switch. Hum Immunol 2008;69(11):681-686
32. Vlad G, D'Agati VD, Zhang QY, et al. Immunoglobulin-like transcript 3-Fc suppresses T-cell responses to allogeneic human islet transplants in hu-NOD/SCID mice. Diabetes 2008;57(7):1878-1886 •• This paper describes a novel approach towards the treatment of diabetes type I building on the powerful immunomodulatory role of ILT3 in transplantation.
33. + suppressor T cells. Nat Immunol 2004;5(5):469-471
34. Lu L, Werneck MB, Cantor H. The immunoregulatory effects of Qa-1. Immunol Rev 2006;212:51-59
35. Sarantopoulos S, Lu L, Cantor H. Qa-1 restriction of CD8+ suppressor T cells. J Clin Invest 2004;114(9):1218-1221 (Pubitemid 40385289)
36. Czesnikiewicz-Guzik M, Lee WW, et al. T cell subset-specific susceptibility to aging. Clin Immunol 2008;127(1):107-118
37. Chung CP, Avalos I, Raggi P, Stein CM. Atherosclerosis and inflammation: insights from rheumatoid arthritis. Clin Rheumatol 2007;26(8):1228-1233 (Pubitemid 47034173)
38. Kaplan MJ. Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 2006;18(3):289-297
39. Weyand CM. Immunopathologic aspects of rheumatoid arthritis: who is the conductor and who plays the immunologic instrument? J Rheumatol Suppl 2007;79:9-14
40. Weyand CM, Goronzy JJ. Ectopic germinal center formation in rheumatoid synovitis. Ann NY Acad Sci 2003;987:140-149 (Pubitemid 36584016)
41. Knedla A, Neumann E, Muller-Ladner U. Developments in the synovial biology field 2006. Arthritis Res Ther 2007;9(2):209
42. Goronzy JJ, Weyand CM. Rheumatoid arthritis. Immunol Rev 2005;204:55-73
43. Weyand CM, Goronzy JJ. T-cell-targeted therapies in rheumatoid arthritis. Nat Clin Pract Rheumatol 2006;2(4):201-210
44. Colmegna I, Diaz-Borjon A, Fujii H, et al. Defective proliferative capacity and accelerated telomeric loss of hematopoietic progenitor cells in rheumatoid arthritis. Arthritis Rheum 2008;58(4):990-1000 (Pubitemid 351564000)
45. Davila E, Kang YM, Park YW, et al. Cell-based immunotherapy with suppressor CD8 + T cells in rheumatoid arthritis. J Immunol 2005;174(11):7292- 7301 (Pubitemid 40705699)
46. Klimiuk PA, Goronzy JJ, Weyand CM. IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J Immunol 1999;162(7):4293-4299 (Pubitemid 29314821)
47. Seo SK, Choi JH, Kim YH, et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 2004;10(10):1088-1094
48. Filaci G, Bacilieri S, Fravega M, et al. Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. J Immunol 2001;166(10):6452-6457 (Pubitemid 32440781)
49. Singh RR, Ebling FM, Sercarz EE, Hahn BH. Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. J Clin Invest 1995;96(6):2990-2996
50. Hahn BH, Singh RR, Wong WK, et al. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum 2001;44(2):432-441 (Pubitemid 32207037)
51. Hahn BH, Singh RP, La Cava A, Ebling FM. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFβ-secreting CD8+ T cell suppressors. J Immunol 2005;175(11):7728-7737 (Pubitemid 41713473)
52. Singh RP, La Cava A, Wong M, et al. CD8+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression. J Immunol 2007;178(12):7649-7657 • This work builds on a series of appealing studies establishing the potential clinical use of peptide-induced immunotolerance as a novel way of treating SLE. The paper provides further insight for the important contribution of pConsensus-induced CD8+ Ts cells and the role of Foxp3 expression. (Pubitemid 46898035)
53. Ferrera F, Hahn BH, Rizzi M, et al. Protection against renal disease in (NZB × NZW)F1 lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide. Arthritis Rheum 2007;56(6):1945-1953
54. Kang HK, Michaels MA, Berner BR, Datta SK. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol 2005;174(6):3247-3255 (Pubitemid 40354027)
55. Kang HK, Liu M, Datta SK. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol 2007;178(12):7849-7858 (Pubitemid 46898057)
56. Weber MS, Hohlfeld R, Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2007;4(4):647-653 (Pubitemid 47499292)
57. Tennakoon DK, Mehta RS, Ortega SB, et al. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 2006;176(11):7119-7129 (Pubitemid 43787894)
58. + regulatory T cells in multiple sclerosis. J Neuroimmunol 2008;195(1-2):121-134
59. Menager-Marcq I, Pomie C, Romagnoli P, van Meerwijk JP. CD8+ CD28- regulatory T lymphocytes prevent experimental inflammatory bowel disease in mice. Gastroenterology 2006;131(6):1775-1785 (Pubitemid 44970462)
60. +/CD103high T cell subset regulates TNF-mediated chronic murine ileitis. J Immunol 2008;180(4):2573-2580
61. Brimnes J, Allez M, Dotan I, et al. Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J Immunol 2005;174(9):5814-5822 (Pubitemid 40593226)
62. James EA, Kwok WW. CD8+ suppressor-mediated regulation of human CD4+ T cell responses to glutamic acid decarboxylase 65. Eur J Immunol 2007;37(1):78-86 • This paper provides a new concept towards understanding how CD8+ Ts cells might be able to protect healthy individuals from type I diabetes. (Pubitemid 46128788)
63. Chatenoud L. OKT3-induced cytokine-release syndrome: prevention effect of anti-tumor necrosis factor monoclonal antibody. Transplant Proc 1993;25(2 Suppl 1):47-51 (Pubitemid 23115826)
64. Chatenoud L. Humoral immune response against OKT3. Transplant Proc 1993;25(2 Suppl 1):68-73 (Pubitemid 23115832)
65. Alegre ML, Peterson LJ, Xu D, et al. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994;57(11):1537-1543
66. Xu D, Alegre ML, Varga SS, et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol 2000;200(1):16-26
67. Ablamunits V, Bisikirska BC, Herold KC. Human regulatory CD8 T cells. Ann NY Acad Sci 2008;1150:234-238
68. + regulatory T cells are responsible for GAD-IgG gene-transferred tolerance induction in NOD mice. Immunology 2009;126(1):123-131